youtube_live
Q3 2026 earnings • released • EPS beat +27.23% • Revenue beat +128.58%
See resultschevron_right
EDIT:NASDAQ
Editas Medicine Inc
$2.53
arrow_downward
-7.98%(-0.22) 1D
Nov 10, 1:56:21 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
$2.70
High
$2.75
Low
$2.48
Mkt. cap
388.65M
Avg. vol.
2.33M
Volume
1.12M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
153.58M
No. of employees
87
Open
$2.70
High
$2.75
Low
$2.48
Mkt. cap
388.65M
Avg. vol.
2.33M
Volume
1.12M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
153.58M
No. of employees
87
News stories
From web sources and news partners
TradingView
·
1 day ago
Editas Medicine, Inc. reports results for the quarter ended September 30 - Earnings Summary
Investing.com
·
1 day ago
Editas Medicine earnings beat by $0.04, revenue topped estimates
kare11.com
·
1 day ago
Editas: Q3 Earnings Snapshot
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
FoundedNov 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com